Safety and antitumor activity from the phase lb study of ramucirumab plus pembrolizumab in treatment-naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)

被引：0
|
作者：
Chau, I. [1 ,2 ]
Bendell, J. [3 ]
Soriano, A. [4 ]
Arkenau, H. [5 ]
Cultreras, J. [6 ]
Santana-Davila, R. [7 ]
Calvo, E. [8 ]
Le Toumeau, C. [9 ]
Zender, L. [10 ]
Mi, G. [11 ]
Schelman, W. [11 ]
Ferry, D. [12 ]
Herbst, R. [13 ]
Fuchs, C. [14 ]
机构：
[1] Royal Marsden Hosp, London, England
[2] Royal Marsden Hosp, Surrey, England
[3] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[4] Florida Canc Specialists Sarah Cannon Res Inst, Englewood, FL USA
[5] HCA Healthcare, Sarah Cannon Res Inst, London, England
[6] Sarah Cannon Res Inst, Florida Canc Specialists, Leesburg, FL USA
[7] Univ Washington, Med Seattle Canc Care Alliance, Seattle, WA 98195 USA
[8] START Madrid CIOCC, Ctr Integral Oncol Clara Campo, Madrid, Spain
[9] Inst Curie, Paris, France
[10] Univ Hosp Tubingen, Internal Med 8, Tubingen, Germany
[11] Eli Lilly & Co, Indianapolis, IN 46285 USA
[12] Eli Lilly & Co, Bridgewater, NJ USA
[13] Yale Sch Med, New Haven, CT USA
[14] Vale Canc Ctr, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SO - 002
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [1] Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF)
    Chau, Ian
    Penel, Nicolas
    Arkenau, Hendrik-Tobias
    Santana-Davila, Rafael
    Calvo, Emiliano
    Soriano, Andres O.
    Mi, Gu
    Jin, Jin
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] Ramucirumab in Combination with Pembrolizumab in Treatment-Naive Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
    Chau, Ian
    Penel, Nicolas
    Soriano, Andres O.
    Arkenau, Hendrik-Tobias
    Cultrera, Jennifer
    Santana-Davila, Rafael
    Calvo, Emiliano
    Le Tourneau, Christophe
    Zender, Lars
    Bendell, Johanna C.
    Mi, Gu
    Gao, Ling
    McNeely, Samuel Clark
    Oliveira, Joana M.
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. CANCERS, 2020, 12 (10) : 1 - 16
  • [3] Safety and efficacy of ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: a multi-disease phase 1 study
    Thuss-Patience, P.
    Vasile, E.
    Chau, I
    Penel, N.
    Mi, G.
    Emig, M.
    Fuchs, C. S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 254 - 255
  • [4] Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).
    Chau, Ian
    Bendell, Johanna C.
    Calvo, Emiliano
    Santana-Davila, Rafael
    Ahnert, Jordi Rodon
    Penel, Nicolas
    Arkenau, Hendrik-Tobias
    Yang, Jing
    Rege, Jessicca
    Mi, Gu
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [5] Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.
    Chau, Ian
    Bendell, Johanna C.
    Calvo, Emiliano
    -Davila, Rafael Santana
    Arkenau, Hendrik-Tobias
    Mi, Gu
    Jin, Jin
    Rege, Jessicca
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive Non-Small Cell Lung Cancer (JVDF)
    Herbst, R.
    Arkenau, H.
    Bendell, J.
    Arrowsmith, E.
    Wermke, M.
    Soriano, A.
    Penel, N.
    Santana-Davila, R.
    Bischoff, H.
    Chau, I.
    Chao, B.
    Ferry, D.
    Mi, G.
    Paz-Ares, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S307 - S307
  • [7] Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).
    Bang, Yung-Jue
    Golan, Talia
    Lin, Chia-Chi
    Kang, Yoon-Koo
    Wainberg, Zev A.
    Wasserstrom, Heather
    Jin, Jin
    Mi, Gu
    McNeely, Samuel
    Laing, Naomi
    Goff, Laura Williams
    Fu, Siqing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
    Herbst, Roy S.
    Arkenau, Hendrik Tobias
    Bendell, Johanna
    Arrowsmith, Edward
    Wermke, Martin
    Soriano, Andres
    Penel, Nicolas
    Santana-Davila, Rafael
    Bischoff, Helge
    Chau, Ian
    Mi, Gu
    Wang, Hong
    Rasmussen, Erik
    Ferry, David
    Chao, Bo H.
    Paz-Ares, Luis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : 289 - 298
  • [9] Fruquintinib plus sintilimab in patients (pts) with either treatment-naive or previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results from a multicenter, single-arm phase II study
    Wei, X.
    Li, J.
    Yuan, H.
    Zhang, W.
    He, W.
    Lu, P.
    Shi, H.
    Tan, P.
    Fan, S.
    Shi, M.
    Su, W.
    Bai, Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S856 - S856
  • [10] A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Mehta, Rutika
    Kim, Richard D.
    Shah, Neal
    Carballido, Estrella M.
    Kim, Youngchul
    Imanirad, Iman
    Kim, Dae Won
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345